Immunotherapy of glioblastoma multiforme.

Trials and tribulations of cancer immunotherapy: the dendritic cell vaccine shows promise in a phase I glioblastoma multiforme trial.

Glioblastoma Multiforme in Children, A Case-Report

ABSTRACT: Glioblastoma multiforme is the most malignant primary brain tumor .It usually occurs in the 5th and 6th decades of life and is rare in childern. In this paper a case of glioblastoma multiforme is reported in a ten year - old child who presented with two week's history of headache with no neurological defect.C.T scan revealed å right frontal mass with massive surrounding oedema. He w...

Cellular immunotherapy directed against human cytomegalovirus as a novel approach for glioblastoma treatment

Glioblastoma multiforme (GBM) has a very poor prognosis, despite multimodal therapy including surgery, radiation and chemotherapy. A novel adoptive immunotherapy that exploits the presence of cytomegalovirus antigens in malignant brain cancer cells has been shown to be safe and elicit potential clinical benefit for the treatment of recurrent GBM.

Cytomegalovirus as a Novel Target for Immunotherapy of Glioblastoma Multiforme

Progress in the treatment of glioblastoma multiforme (GBM) over the last few decades has remained marginal and GBM is still universally fatal with short survival times after initial diagnosis. Much research is focused on finding new therapeutics for GBM and immune-based approaches have shown great promise. The detection of cytomegalovirus (CMV) antigens in malignant cells has suggested that tre...

Comprehensive analysis of PD-L1 expression in glioblastoma multiforme

Glioblastoma multiforme are highly malignant brain tumours with frequent genetic and epigenetic alterations. The poor clinical outcome of these tumours necessitates the development of new treatment options. Immunotherapies for glioblastoma multiforme including PD1/PD-L1 inhibition are currently tested in ongoing clinical trials. The purpose of this study was to investigate the molecular backgro...

Advances in Immunotherapy for Glioblastoma Multiforme

Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor in adults. Patients with GBM have poor outcomes, even with the current gold-standard first-line treatment: maximal safe resection combined with radiotherapy and temozolomide chemotherapy. Accumulating evidence suggests that advances in antigen-specific cancer vaccines and immune checkpoint blockade in other advanced ...